Melatonin
Half-Life (t½) PO: 42m · SL: 30m
Formula C13H16N2O2
Molecular Weight 232.28 g/mol Pharmacological Mechanism MT1/MT2 agonist; entrains the circadian clock bmal1 per cry circadian rhythm.
Half-Life & Elimination Curve (PO: 42m · SL: 30m) 100% 50% 25% 12.5% 0% 0h 0×t½ 42m 1×t½ 1.4h 2×t½ 2.1h 3×t½ 2.8h 4×t½ 3.5h 5×t½ 0×t½ (0h): 100% remaining (~1.24 µg/L) 1×t½ (42m): 50% remaining (~0.621 µg/L) 2×t½ (1.4h): 25% remaining (~0.31 µg/L) 3×t½ (2.1h): 12.5% remaining (~0.155 µg/L) 4×t½ (2.8h): 6.3% remaining (~0.0776 µg/L) 5×t½ (3.5h): 3.1% remaining (~0.0388 µg/L) Plasma (PO) t½ Decay (42m) Effect Site (ke0)
0×t½ 0h 100% (1.24 µg/L) 1×t½ 42m 50% (0.621 µg/L) 2×t½ 1.4h 25% (0.31 µg/L) 3×t½ 2.1h 12.5% (0.155 µg/L) 4×t½ 2.8h 6.3% (0.0776 µg/L) 5×t½ 3.5h 3.1% (0.0388 µg/L) Dosing Guidelines Oral (PO): Typical 0.5 mg (Range: 0.3–5 mg)Sublingual (SL): Typical 0.5 mg (Range: 0.3–3 mg)Pharmacokinetic Parameters Oral (PO): Bioavailability (F): 15% · Volume of Distribution (Vd): 35 L · Absorption (ka): 3 h⁻¹ (t½ka ≈ 14m) [PMID 37438493 ]Sublingual (SL): Bioavailability (F): 50% · Volume of Distribution (Vd): 35 L · Absorption (ka): 6 h⁻¹ (t½ka ≈ 7m) [PMID 37438493 ]Effect-Site Equilibration (ke0): 0.5 h⁻¹ (equilibration half-time t½ke0 ≈ 1.39h) [PMID 26008214 ]Receptor Binding & Occupancy Pathways It Modulates Target Organ Systems nervous Endocrine System digestive Notes Lower doses (0.3mg) often outperform high doses for sleep onset. PO has heavy first-pass; SL bypasses much of it. MT1 Ki ~80 pM = 0.0000186 mg/L, MT2 Ki ~270 pM = 0.0000626 mg/L (melatonin MW 232 g/mol). Therapeutic plasma at 0.5 mg PO peaks ~80-100 pg/mL = ~1e-4 mg/L, well above both receptor EC50s — both are saturated within minutes of dosing.
Chemical Structure & Identifiers InChIKey: DRLFMBDRBRZALE-UHFFFAOYSA-NSMILES: CC(=O)NCCC1=CNC2=C1C=C(C=C2)OCReferences Directory Compounds Registry Human Biology Hub